\-\ Texto\\:\\ \ \(0\)\
\-\ unremarkable\\ pe\\ and\\ laboratory\\ results\ \(0\)\
\-\ discontinue\\ use\\ of\\ oral\\ contraceptives\ \(0\)\
\-\ 2cm\\ mass\\ in\\ liver\\ showing\\ hyperattenuation\\ during\\ early\\ \\(arterial\\)\\ phase\\ of\\ contrast\\ enhanced\\ ct\\ and\\ isoattenuation\\ during\\ late\\ \\(portal\\ venous\\)\\ phase\\.\ \(0\)\
\-\ hypervascular\\ hepatic\\ mass\\:\\ possible\\ hepatic\\ adenoma\ \(0\)\
\-\ hepatic\\ adenoma\ \(5\)\
\-\ focal\\ nodular\\ hyperplasia\ \(9\)\
\-\ hepatic\\ hemangioma\ \(3\)\
\-\ hypervascular\\ metastasis\ \(0\)\
\-\ hepatocellular\\ carcinoma\ \(28\)\
\-\ healthy\\ 34\\ y\\/o\\ female\\ taking\\ ocps\\ referred\\ for\\ triphasic\\ liver\\ scan\\ following\\ incidental\\ discovery\\ of\\ hepatic\\ mass\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hepatic\\:\\ 0\\.49734853955500163\ \(0\)\
\-\ hypervascular\\:\\ 0\\.264139651566943\ \(0\)\
\-\ phase\\:\\ 0\\.21376464651032712\ \(0\)\
\-\ adenoma\\:\\ 0\\.1991645758333205\ \(0\)\
\-\ isoattenuation\\:\\ 0\\.19087527607064667\ \(0\)\
\-\ triphasic\\:\\ 0\\.184575969949378\ \(0\)\
\-\ discontinue\\:\\ 0\\.17968984852117942\ \(0\)\
\-\ liver\\:\\ 0\\.17233338501700418\ \(0\)\
\-\ hyperattenuation\\:\\ 0\\.17232219574490074\ \(0\)\
\-\ ocps\\:\\ 0\\.16939829050543825\ \(0\)\
\-\ contraceptives\\:\\ 0\\.16681922330403584\ \(0\)\
\-\ during\\:\\ 0\\.15823175889922145\ \(0\)\
\-\ discovery\\:\\ 0\\.15289312809374467\ \(0\)\
\-\ mass\\:\\ 0\\.14313353629507036\ \(0\)\
\-\ 2cm\\:\\ 0\\.12971306265254398\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.12841188210580975\ \(0\)\
\-\ taking\\:\\ 0\\.12098415586835085\ \(0\)\
\-\ portal\\:\\ 0\\.11953350878313869\ \(0\)\
\-\ late\\:\\ 0\\.1179107840904104\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.11387512928209201\ \(0\)\
\-\ 34\\:\\ 0\\.10885931292665911\ \(0\)\
\-\ showing\\:\\ 0\\.10784851364476195\ \(0\)\
\-\ healthy\\:\\ 0\\.1059569702323817\ \(0\)\
\-\ hemangioma\\:\\ 0\\.10506914201828722\ \(0\)\
\-\ pe\\:\\ 0\\.10326076301904795\ \(0\)\
\-\ arterial\\:\\ 0\\.10286383197724441\ \(0\)\
\-\ oral\\:\\ 0\\.10003848697710088\ \(0\)\
\-\ nodular\\:\\ 0\\.09946970791100032\ \(0\)\
\-\ results\\:\\ 0\\.09733174149636262\ \(0\)\
\-\ use\\:\\ 0\\.09557123244622247\ \(0\)\
\-\ enhanced\\:\\ 0\\.09510631555744817\ \(0\)\
\-\ incidental\\:\\ 0\\.09258866989103458\ \(0\)\
\-\ referred\\:\\ 0\\.0924252604545485\ \(0\)\
\-\ metastasis\\:\\ 0\\.0915476770970034\ \(0\)\
\-\ laboratory\\:\\ 0\\.09070391459398916\ \(0\)\
\-\ early\\:\\ 0\\.09003695655061099\ \(0\)\
\-\ venous\\:\\ 0\\.0891781498952592\ \(0\)\
\-\ possible\\:\\ 0\\.08463151996306845\ \(0\)\
\-\ unremarkable\\:\\ 0\\.08373765042934234\ \(0\)\
\-\ following\\:\\ 0\\.07493238823591512\ \(0\)\
\-\ focal\\:\\ 0\\.07471378313040773\ \(0\)\
\-\ carcinoma\\:\\ 0\\.07471378313040773\ \(0\)\
\-\ scan\\:\\ 0\\.07410599722359063\ \(0\)\
\-\ of\\:\\ 0\\.07333130133385972\ \(0\)\
\-\ contrast\\:\\ 0\\.060689810865512304\ \(0\)\
\-\ female\\:\\ 0\\.060273438092591884\ \(0\)\
\-\ and\\:\\ 0\\.05162104703544186\ \(0\)\
\-\ ct\\:\\ 0\\.04755330668341891\ \(0\)\
\-\ for\\:\\ 0\\.03785838417233859\ \(0\)\
\-\ in\\:\\ 0\\.03107283337442661\ \(0\)\
